Dr Jane Wolstenholme
BA(Hons), MSc, PhD
Associate Professor of Health Economics
I have over 25 years of experience in conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. I have been a health economist at HERC since 1998, prior to that a research associate at the University of Nottingham.
My research programme has focused on the health economics of cancer, with current research on trial-based evaluations and methodology related to prostate, breast and head and neck cancer. Previous published research relates to the economic evaluation of interventions for prostate, breast, cervical and lung cancer.
My main research interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. I am principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care and in-vitro diagnostics.
I am a health economics adviser for the NIHR RDS South Central and the lead health economist for the NIHR Community Healthcare Medtech and In Vitro Diagnostics Co-operative, Oxford University.
I supervise MSc and DPhil students. Examples of current doctoral research:
- Exploring the cost-effectiveness of chronic disease prevention strategies using local area chronic disease scenario modelling.
- Developing a modelling framework for providing individualised estimates of comparative outcomes and cost-effectiveness for competing radiotherapy technologies in cancer patients.
I have published widely and I’m co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Survival, Dependency, and Health-Related Quality of Life in Patients With Ruptured Intracranial Aneurysm: 10-Year Follow-up of the United Kingdom Cohort of the International Subarachnoid Aneurysm Trial.
Hua X. et al, (2021), Neurosurgery, 88, 252 - 260
Improving outcomes for women diagnosed with early breast cancer through Adherence to adjuvant endocrine therapy (SWEET)
Sharp L. et al, (2020), BREAST CANCER RESEARCH AND TREATMENT, 180, 544 - 545
A randomised controlled trial of Partial prostate Ablation versus Radical prosTatectomy (PART) in intermediate risk, unilateral clinically localised prostate cancer: a feasibility study
Hamdy FC. et al, (2018), Health Technology Assesment, 22, 1 - 96
Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.
Hamdy FC. et al, (2018), Health Technol Assess, 22, 1 - 96
Preference-based measures to obtain health state utility values for use in economic evaluations with child-based populations: a review and UK-based focus group assessment of patient and parent choices.
Wolstenholme JL. et al, (2018), Qual Life Res, 27, 1769 - 1780